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Summary
The pituitary hormone prolactin (PRL) is best known for
its role in the regulation of lactation. Recent evidence
furthermore indicates PRL is required for normal repro-
ductioninrodents.Here,wereportontheinsertionoftwo
transposon-like DNA sequences in the human prolactin
gene, which together function as an alternative promoter
directing extrapituitary PRL expression. Indeed, the
transposable elements contain transcription factor bind-
ing sites that have been shown to mediate PRL transcrip-
tion in human uterine decidualised endometrial cells and
lymphocytes. We hypothesize that the transposon inser-
tion event has resulted in divergent (pituitary versus
extrapituitary) expression of prolactin in primates, and
in differential actions of pituitary versus extrapituitary
prolactin in lactation versus pregnancy respectively.
Importantly, the TE insertion might provide a context for
someoftheconflictingresultsobtainedinstudiesofPRL
function in mice and man. BioEssays 28:1051–1055,
2006.  2006 Wiley Periodicals, Inc.
Introduction
The polypeptide hormone prolactin (PRL) is produced mainly
by the lactotrope cells of the anterior pituitary and, in
mammals, its most apparent function is the regulation of
lactation.
(1) In addition, PRL has been attributed an important
role in reproduction, as was illustrated by the observation that
PRL
 /  mice not only have defects in mammopoiesis but are
alsosterile.
(2)Interestingly,althoughthebulkofPRLcirculating
in serum is produced by the lactotrope cells of the pituitary,
PRL is also expressed extrapituitarily by various tissues
including uterine decidualised endometrial cells and leuko-
cytes.
(3) The human PRL gene is located on chromosome 6
and was initially described as containing five exons and four
introns,withanoveralllengthof10kilobases(kB).
(4)However,
when extrapituitary PRL expression was shown in human
lymphocytes and subsequently in human decidual cells, it
was revealed that, in these extrapituitary tissues, the PRL
messenger RNA (mRNA) was longer than its pituitary
counterpart.
(5,6) The reason for this discrepancy is that, in
human decidua and lymphocytes, PRL transcription is driven
byanalternativepromoter,whichislocated5.8kbupstreamto
the pituitary transcription start site, resulting in the transcrip-
tion of an extra exon, named exon 1a (Fig. 1).
(7,8)
Alternative promoter usage is not an uncommon phenom-
enon.Landryetal,byscreeningdatabasesfor transcriptswith
alternative first exons, estimated that approximately 18% of
human genes have alternative promoters.
(9) According to a
more recent paper, the rate of alternative promoter usage is
evenhigherandapproximatelyhalfofthehumangenomewas
predicted to be transcribed via multiple promoters.
(10) In the
case of the PRL gene, the alternative initial exon does not
contain coding sequence and hence transcription from the
alternative promoter does not lead to the generation of
protein isoforms. However, the extra exon could contribute
to the expansion of the transcriptional and/or translational
‘‘repertoire’’ of the PRL gene. Indeed, alternative promoters
often evolve in genes with complex patterns of transcriptional
regulation. For instance, there are many examples of genes
where an alternative promoter confers tissue-specific expres-
sion, directs expression as a function of the differentiation
stage and/or regulates expression level.
(11–15) In addition, the
variant 50 untranslated regions (UTRs) might influence the
stabilityor translationalefficiencyofthealternativelypromoted
messages.
(16–18)
Two transposable elements (TEs) direct
extrapituitary PRL expression
To date, the use of an alternative promoter to regulate
extrapituitary PRL expression has only been described in
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Hypotheseshumans and in the rhesus macaque.
(7,8,19) Intriguingly, by
screening the PRL gene using the UCSC Genome Browser
anditsRepeatMaskerfacility(http://genome.ucsc.edu/cgi-bin/
hgGateway), we observed that the proximal part of the
extrapituitary PRL promoter, as well as exon 1a and a part of
intronic sequence (Chr6: 22,410,692–22,411,189¼498 bp),
occur within a long terminal repeat (LTR)-like transposable
element (TE) of the medium frequency reiterated repeat
(MER)family.
(20)TheLTRsequence(namedMER39)belongs
to the ERV1 class of endogenous retroviruses and it is also
present in the Rhesus macaque and chimpanzee PRL gene,
but not in dog, mouse or rat genomes (Fig. 1). This indicates
that insertion of the LTR element occurred at least 25–
30 million years ago, before the divergence of Old World
monkeys from higher apes. In addition, an older TE, MER20,
belonging to the MER1 class of DNA transposons, has pro-
videdthesequencebetween 189and 387oftheextrapituit-
ary PRL promoter (Chr6: 22,411,225–22,411,422¼198 bp).
This TE is also present in the rat and dog, but is not evident in
mice (Fig. 1). It is likely that the MER20 TE integrated before
mammalian radiation, 70–80 million years ago, but is not
found by Repeatmasker in mice due to the higher neutral
mutation rate in rodents, making ancient TEs difficult to
detect.
(21)SeveralreportshavedemonstratedthatTE-derived
sequences can regulate nearby human genes. In the majority
ofthesecases,theLTRactsasagenepromoter,isoftenoneof
multiple alternative promoters and usually does not alter the
coding sequence.
(14,15,22–24)
PRL transcription via the extrapituitary PRL promoter
has been most intensively studied in decidual cells and in
lymphocytes.In both cell types,promoter activityis stimulated
by cAMP and, interestingly, the responsiveness to cAMP is in
part mediated by an imperfect cAMP-responsive element
(CRE),locatedwithintheMER39LTR(Fig.1).
(25,26)Moreover,
two CAAT/enhancer binding protein (C/EBP) sites in the
neighbouring 50 promoter sequence, which is derived from
a MER20 transposon, have also been shown to be obligate
for cAMP responsiveness both in decidual cells and in
Figure 1. Schematic representation oftheorganisationof thePRLgene. Differential promoter usageresultsin thetranscriptionof either
the short, pituitary, mRNA or the long, extrapituitary, mRNA, containing the extra exon 1a. Since exon 1a is non-coding, both mRNAs give
rise to an identical PRL protein. The promoter directing pituitary PRL expression harbours several binding sites for the pituitary-specific
transcription factor Pit-1, which is essential for pituitary PRL expression. The best-described stimulus for extrapituitary PRL expression
(in decidua and lymphocytes) is cAMP , which acts via a CRE and several C/EBP sites in the 50 region flanking exon 1a. The upper panel
shows a graphical representation of the conservation (compared to the human sequence) of the chromosome sequence containing the
extrapituitary exon 1a (data obtained via the USCS Genome Browser). Notice that exon 1a and part of the 50 and 30 flanking intronic
sequences are localized within a 498 bp long MER 39 LTR-like sequence, which has the same transcriptional orientation as the gene.
Moreover, an additional 198 bp of the 50 flanking region of exon 1a are provided by a MER20 TE. The MER39 TE is present in human and
chimpbutnotindog,mouseorratgenomes,whereastheMER20TEispresentinhuman,chimp,dogandratgenomes,butisnotdetectable
inthemousegenome.Interestingly,thetranscriptionfactorbindingsitesthathavebeenshowntomediateextrapituitaryPRLexpressionare
located within the TEs.
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to cooperate to promote extrapituitary PRL expression in
primates.
(27,28)
In search of a role for primate
extrapituitary PRL
Toourknowledge,therearenoreportsofmutationsinthePRL
gene in humans. This could mean that such mutations do not
have any important phenotypic consequences, or, alterna-
tively, that they are lethal. PRL deficiency has been described
in individuals with mutations in the Pit-1 transcription factor,
which is essential for transcription of pituitary PRL and other
pituitary hormones.
(29) However, extrapituitary PRL expres-
sion does not depend on Pit-1 and hence is probably not
affected in these subjects. In addition, few cases of women
with isolated PRL deficiency have been reported that became
apparentonlybecausethesewomensufferedfromalactogen-
esis (after normal pregnancies).
(30–33) In these case studies,
the involvement of a genetic defect in the observed PRL
deficiency was not addressed. Importantly, in the above
studies, PRL deficiency was defined as undetectable PRL
levels in serum and there is no evidence that there was in fact
no local, extrapituitary, PRL production. The assays that are
routinely used in the clinic to detect PRL in serum typically
have detection limits of around 500 pg/ml, which is adequate
for detection of endocrine PRL, but probably not for detection
of autocrine or paracrine PRL, that is secreted extrapituitarily.
Therefore, to establish whether these ‘‘PRL-deficient’’ indivi-
duals are truly PRL knock-outs,extrapituitary PRL expression
should also be assessed.
Whereas women with isolated PRL deficiency, as demon-
strated by undetectable serum PRL levels, can reproduce
normally but do not lactate, a recent paper describes a
correlation between defective decidual PRL expression and
implantation failure, suggesting extrapituitary PRL might play
a role in the regulation of reproduction.
(34) An intriguing
question is whether alternative promoter usage, due to TE
insertions, has led to different functions for pituitary and
extrapituitaryPRL,i.e.inlactationandpregnancy,respectively.
It is conceivable that bifurcated PRL expression is energeti-
callyfavourableandperhapsadvantageousinanevolutionary
perspective, because high PRL levels in the amniotic fluid
required for successful reproduction are delivered by the
decidua, and hence secretion of large amounts of PRL by the
pituitarycanbelimitedtotheperiodoflactation.Aninteresting
parallelcanbedrawnwiththecaseoftheleptingene.Leptinis
a circulating hormone that is expressed byadipose tissue and
is involved in the regulation of energy homeostasis, as well as
neuroendocrine and reproductive systems. In mice, serum
leptin levels increase dramatically during pregnancy. In man
there is only a moderate increase in serum leptin levels, yet
during pregnancy, leptin is produced by the placenta and
accumulates in the amniotic fluid. Interestingly, it has been
shownthatplacentalleptinexpressioninhumansisalsodriven
bya primate-specific TE inserted in the human leptin gene.
(35)
PRL
 /  mice, which are infertile, lack pituitary as well
as extrapituitary PRL, so it is possible that, in mice also,
extrapituitary (decidual) PRL plays a role in reproduction.
However, whereas there is ample evidence for extrapituitary
PRL expression in rodents and other non-primates, the PRL
mRNAs detected in these species have not been character-
ized in detail.
(3) Unless evidence is provided for the transcrip-
tion of PRL mRNAs with alternative first exons, it is most likely
that the described PRL transcripts are under the control of the
same promoter that is active in the pituitary. Of course, tissue-
specific functions of PRL may still exist independently of
alternative promoter usage in non-primates.
Addition of an alternative promoter through TE insertion in
primates may also have led to specialized functions of PRL in
thehumanimmunesystem.Apointofcontroversyisthatthere
are many indications for a role of PRL in the human immune
system, whereas PRL or PRL-R knockout mice are not
immune deficient.
(2,36) It could be that, in primates, local
PRL, produced in the immune system under the control of the
alternative upstream promoter has a special, cytokine-like,
function. Interestingly, in species, such as the mouse, the rat
and the cow, but not in primates, the PRL gene has expanded
to yield a large family of paralogous genes closely related to
PRL. Mice possess at least 26 paralogous PRL genes and
current information indicates that not all members of this PRL
family use the PRL receptor.
(37) Neither knocking out PRL nor
the PRL-R would therefore create a model system mimicking
the situation of a human PRL knockout. One could speculate
that the lack of expansion of the PRL gene in primates is
compensated by the mechanism of alternative promoter
usage and that, in primates, certain functions of PRL or
PRL-like proteins are exerted by extrapituitary PRL under the
control of the alternative promoter.
Perspectives
In summary, we believe further research should be directed
towards elucidating the consequences and the importance of
the primate-specific organization of the PRL gene. As has
been shown for other examples of TEs acting as gene
promoters, it would be interesting to determine if the TEs
involved in PRL expression possessed the CREB site and
other regulatory motifs at the time of insertion and if these
motifs have been selectively conserved throughout primate
evolution.
(38) If so, it would argue for an important role for
extrapituitary PRL expression. In view of the recent observa-
tion that there is a relationship between decidual PRL expres-
sion and reproductive disorders, further research should
be directed towards assessing the molecular basis of the
reported defects in extrapituitary PRL expression and the
consequences of these defects in reproduction. In addition, it
wouldbeinterestingtoevaluateextrapituitaryPRLexpression
Hypotheses
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that extrapituitary PRL is involved in reproduction is correct,
then one would expect to detect PRL in decidual cells from
these women.
Unfortunately, whereas the mouse model has been an
invaluable tool to study human biology and disease, data
regarding extrapituitary PRL expression cannot be readily
extrapolated from mice to man. Rodent transgenic knock-in
approachescouldbeusefulthoughtostudythefunctionofthe
alternative promoter in vivo. Transgenes of interest could
therefore include either the whole hPRL locus, or the pituitary
promoter alone or the alternative promoter alone, either in
normal animals or in PRL
 /  mice. This approach would allow
for an unambiguous evaluation of the contribution of the two
PRL promoters to tissue-specific PRL expression. Addition-
ally,ifourspeculationisright,onewouldexpectthatknock-inof
hPRLexpressionfromtheextrapituitarypromoteralonewould
besufficienttorescuePRL
 / micefrominfertility.However,as
it isunlikelythathumanreproductioncanbemimickedentirely
in mice, primate (for instance Rhesus monkey) models will be
indispensable to gain a better insight into the role of human
extrapituitary PRL expression.
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